Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology

Rhea-AI Summary

Ludwig Enterprises Inc. (OTC PINK:LUDG) has announced Revealia™, an AI-powered cancer screening technology. This revolutionary mail-order non-invasive cheek swab test aims to transform early cancer detection with continuously improving accuracy. At its core is the Revealia Inflammatory Index (RII), which uses advanced AI to analyze mRNA-based genetic signals associated with cancer presence.

Developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division, the AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. Key features include optimization of sensitivity and specificity trade-offs, continuous learning from an expanding dataset, and analysis of mRNA samples from over 40 multipurpose medical clinics across the United States.

Positive

• Introduction of Revealia™, a potentially revolutionary cancer screening tool
• AI-driven technology that continuously improves accuracy
• Non-invasive and convenient mail-order cheek swab test
• Analysis of mRNA samples from over 40 multipurpose medical clinics across the US

Negative

• None.

Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning

SPARKS, NV / ACCESSWIRE / September 24, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce Revealia™, which is set to become the world's most convenient cancer screening tool. This simple mail-order non-invasive cheek swab has the potential to save lives by detecting early signs of cancer.

At the heart of Revealia™ is the Revealia Inflammatory Index (RII), a sophisticated method for quantifying cancer risk. The RII leverages cutting-edge artificial intelligence to analyze mRNA-based genetic signals associated with the presence of cancer.

This proprietary technology was developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division. Our AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. This approach allows for ongoing refinement of our cancer detection capabilities.

Key features of our AI approach include:

• Optimization of the trade-off between sensitivity and specificity

• Continuous learning from an expanding dataset

• Analysis of mRNA samples from over 40 multipurpose medical clinics across the United States

Looking Ahead

"Ludwig has uncovered game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CSO. "As we prepare to launch Revealia™, we're excited about the potential impact of our AI-driven approach for early cancer detection."

Ludwig Enterprises continues to advance its mission of providing accessible, accurate, and non-invasive cancer screening tools to improve public health.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc., a pioneering biotechnology company, is at the forefront of mRNA genomics and machine learning AI technology. Our mission is to combat chronic inflammation, a key factor in diseases like cancer and heart disease that account for over 50% of global deaths. Through innovative solutions like Revealia™, we aim to revolutionize early detection and prevention strategies in healthcare.

For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CSO
marvin@ludwigent.com
www.ludwigent.com

Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com

Contact Information

Mike Sheikh
Investor Relations
mike@resourcesunlimtedllc.com

SOURCE: Ludwig Enterprises Inc

View the original press release on accesswire.com

FAQ

What is Revealia™ and how does it work for cancer screening?

Revealia™ is an AI-powered cancer screening technology developed by Ludwig Enterprises Inc. (LUDG). It uses a non-invasive cheek swab test to analyze mRNA-based genetic signals associated with cancer presence, employing machine learning algorithms for continuous improvement in accuracy.

Who developed the AI technology behind Revealia™ for Ludwig Enterprises (LUDG)?

The AI technology behind Revealia™ was developed by Dr. Kyle Ambert, PhD, who is the Director of Data Science at Nike's Consumer Data Science Division.

What is the Revealia Inflammatory Index (RII) used in Ludwig Enterprises' (LUDG) cancer screening technology?

The Revealia Inflammatory Index (RII) is a sophisticated method used in Ludwig Enterprises' (LUDG) Revealia™ technology for quantifying cancer risk. It leverages advanced AI to analyze mRNA-based genetic signals associated with the presence of cancer.

How does Ludwig Enterprises (LUDG) improve the accuracy of its Revealia™ cancer screening technology?

Ludwig Enterprises (LUDG) improves the accuracy of Revealia™ through machine learning algorithms that continuously update and improve as new patient data is received. The AI technology also optimizes the trade-off between sensitivity and specificity and learns from an expanding dataset.